Drug Profile
Research programme: tumour necrosis factor-alpha convertase inhibitors - Wyeth
Alternative Names: TMI-1Latest Information Update: 11 Sep 2008
Price :
$50
*
At a glance
- Originator Amgen
- Developer Wyeth
- Class Small molecules
- Mechanism of Action Matrix metalloproteinase inhibitors; Tumour necrosis factor-alpha convertase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 11 Sep 2008 No development reported - Preclinical for Rheumatoid arthritis in USA (PO)
- 17 Apr 2007 Data presented at the 233rd American Chemical Society National Meeting (ACS-2007) added to the Rheumatic Disease pharmacodynamics section
- 27 May 2004 Preclinical trials in Rheumatoid arthritis in USA (PO)